Journal article
Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
Atherosclerosis. Supplements, Vol.4(4), pp.61-65
2003
DOI: 10.1016/S1567-5688(03)00035-7
PMID: 14664904
Abstract
Hyperhomocysteinemia is an emerging risk factor for cardiovascular disease and stroke. The mechanisms underlying the pathophysiology of hyperhomocysteinemia are not completely defined, but endothelial dysfunction resulting from impaired bioavailability of nitric oxide is a consistent finding in experimental models. One potential mechanism for decreased nitric oxide bioavailability is inhibition of endothelial nitric oxide synthase by its endogenous inhibitor, asymmetric dimethylarginine (ADMA). Elevated plasma levels of ADMA have been found in association with hyperhomocysteinemia and endothelial dysfunction in both animals and humans. Additional studies are required to determine the mechanisms by which ADMA accumulates in hyperhomocysteinemia and to define the importance of ADMA in the endothelial dysfunction of hyperhomocysteinemia in vivo.
Details
- Title: Subtitle
- Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
- Creators
- Steven R Lentz - Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USARoman N Rodionov - Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USASanjana Dayal - Veterans Affairs Medical Center, Iowa City, IA, USA
- Resource Type
- Journal article
- Publication Details
- Atherosclerosis. Supplements, Vol.4(4), pp.61-65
- DOI
- 10.1016/S1567-5688(03)00035-7
- PMID
- 14664904
- NLM abbreviation
- Atheroscler Suppl
- ISSN
- 1567-5688
- eISSN
- 1878-5050
- Publisher
- Elsevier Ireland Ltd
- Language
- English
- Date published
- 2003
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Iowa Neuroscience Institute; Fraternal Order of Eagles Diabetes Research Center; Internal Medicine
- Record Identifier
- 9984065380002771
Metrics
18 Record Views